News

The filing is for the first oral antiviral therapy, and is based off its phase 3 trial.

The TakeMeHome program, a public-private partnership to distribute HIV self-test home kits to at-risk populations, is reaching at-risk individuals who weren’t otherwise accessing testing.

Providers offer their insights on this important topic.

If the FDA approves maribavir, it will be the first and only treatment for adults with CMV as a result of a hematopoietic stem cell transplant or solid organ transplant.

A global study of C. difficile isolates worldwide found a very high prevalence of the bacteria on shoe soles.

It can help inform appropriate antibiotic prescribing, but likely would only form part of testing protocol, experts say.

The HIV In-hospital Mortality Prediction (HIV-IMP) risk score showed good discrimination and calibration and may be useful in guiding clinical decision-making.

A recent study measured premature deaths among people with HIV by sex, race, and HIV risk factor.

A new study shows Medicare-aged patients being treated in hospitals saw more of these types of infections, creating a greater burden on care and costs, and showing an increased mortality rate.

Qatar has the highest mRNA vaccine coverage in the world, but their vaccinated population is experiencing significant waning in vaccine efficacy, leading to breakthrough infections.

Malaria has afflicted humanity for thousands of years, and the parasite is especially deadly for children and babies. The WHO has recommended the first malaria vaccine be deployed across sub-Saharan Africa.

This investigational therapy could be the first implantable form of PrEP.

AstraZeneca’s long-acting antibody, AZD7442, would act as a supplement to vaccination and could provide up to a year of protection against symptomatic COVID-19.

People who inject drugs are at high-risk for HIV infection, but very few are interested in PrEP prescriptions.

US federal health agencies are recommending an additional shot for this diverse patient population, and here on some insights about vaccine efficacy and breakthrough infections in these groups.

This study confirmed reports from the CDC and Israel Ministry of Health that found the Pfizer-BioNTech vaccine waned after 6 months.

A study found similar rates of acute respiratory illness-related visits across race/ethnicity when all healthcare settings were combined, but ARI visits differed for race/ethnicity groups across ambulatory, emergency, and hospital settings.

Learn more about new test for diagnosing early Lyme disease in a Q&A with Adaptive Biotechnologies.

Self-testing for HIV is fast and easy, and test kits can be completed at a health department with the help of staff or at home and dropped off later.

If the company gets approval it would be the first dispersible single tablet regimen containing dolutegravir.

As more agents expand the capability and variety of PrEP options, investigators consider what questions remain about the drug class.

Following the approval of cabotegravir-rilpivirine earlier this year, experts are looking forward to an expansion of the drug class for HIV.

The combination therapy's non-inferior efficacy to heavier TAF regimens may indicate a greater embrace of 2-drug regimens for people living with HIV.

Monica McArthur, MD, PhD, discusses why to-be-authorized COVID-19 vaccine doses for children may not be tiered for patient risk as they were for adults.

New late-breaking data illuminate the specific efficacy of the combination monoclonal antibodies.

The findings have supported the launch of a phase 3 trial called EVERGREEN, which is now underway.

A conversation in consideration of the high-risk psychosocial comorbidities the aging HIV population may face through COVID-19.

A new study from IDWeek showed most observed children previously infected with SARS-CoV-2 retained antibodies over 6 months.